RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer.

The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...

The firm has raised its target on zanzalintinib’s probability of success in CRC, which it now pegs at 50%, but views the success of the trial as “a toss-up” given the history of cabometyx ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

In addition to Cabozantinib, Exelixis is developing zanzalintinib, a next-generation tyrosine kinase inhibitor. Analysts project that zanzalintinib could generate $5 billion in revenue by 2033, ...

The company’s flagship product, CABOMETYX®, continues to make waves alongside promising treatments like Zanzalintinib, XB010, and XL495. With many of these therapies still in trial phases or awaiting ...

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.